TARS Tarsus Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

   TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year

   Cash runway expected into at least 2026

   
   IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for eye diseases, today announced financial results for the first quarter ended March 31, 2022, and recent business achievements.

   "In the first quarter, we took important steps towards becoming a leading eye care pharmaceutical company. We reported strong and consistent Saturn-2 data, further validating the safety and efficacy of TP-03 and positioning…

   View Full Article
2. 06 May 2022 Tarsus to Present at Bank of America 2022 Healthcare Conference

   IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus, will present a corporate update at the Bank of America 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00pm PT / 3:00pm ET.
   

   A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website at www.tarsusrx.com. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

   About Tarsus Pharmaceuticals, …

   View Full Article
3. 05 May 2022 Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

   IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on coexisting bacterial burden for patients with Demodex blepharitis. Both studies were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.
   

   Accepted abstracts include:

   • The Impact of Demodex Blepharitis on Patients and Healthcare System: Results …

   View Full Article
4. 03 May 2022 Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

   IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (the "Company" or "Tarsus"), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an upsized underwritten public offering of 5,600,000 shares of common stock at a public offering price of $13.50 per share, which represents $75.6 million of common stock, before underwriting discounts and commissions. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering…

   View Full Article
5. 02 May 2022 Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

   IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (the "Company" or "Tarsus"), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of an underwritten public offering of $50 million of shares of its common stock. Tarsus also expects to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are…

   View Full Article